Premium
Establishment of optimized ELISA system specific for HLA‐G in body fluids
Author(s) -
OujiSageshima N.,
Geraghty D. E.,
Ishitani A.,
Hatake K.,
Ito T.
Publication year - 2016
Publication title -
hla
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.347
H-Index - 99
eISSN - 2059-2310
pISSN - 2059-2302
DOI - 10.1111/tan.12919
Subject(s) - hla g , human leukocyte antigen , immunoprecipitation , monoclonal antibody , gene isoform , receptor , antibody , immunology , antigen , microbiology and biotechnology , biology , gene , biochemistry
Recently, human leukocyte antigen‐G ( HLA‐G ) has been a focus in the field of reproductive immunology, tumor progression and transplantation, because of its inhibitory function as ligand to the inhibitory receptors leukocyte immunoglobulin‐like receptors ( LILR ) B1 and LILRB2 . The HLA‐G is expressed in distinct mRNA isoforms, one of which encodes a soluble HLA‐G ( sHLA‐G ) protein, detectable by sandwich ELISA . Therefore, sHLA‐G ELISAs have been used as a noninvasive diagnosis system. While a number of sHLA‐G ‐specific ELISAs have been described, our prior studies showed that data obtained by the conventional ELISA system detecting sHLA‐G in body fluids was not consistent with the data obtained from immunoprecipitation ( IP )/immunoblotting ( IB ). Therefore, we established an optimized ELISA system described in this report, which yields results consistent with IP / IB analysis. Using this system, we determined sHLA‐G protein in amniotic fluids, and found that sHLA‐G levels at preterm (∼36 weeks) were clearly higher than those at term (37–41 weeks). These data and supporting experiments showed that the ELISA system we established can be an useful tools for the detection of sHLA‐G protein in body fluids than the conventional ELISA system.